HIV Market Forecast

NEW YORK, March 19, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

HIV Market Forecast

http://www.reportlinker.com/p0128202/HIV-Market-Forecast.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

This report explores key issues in HIV across the US and five major EU markets (France, Germany, Italy, Spain, and the UK). It contains an assessment of key HIV drugs, a discussion of HIV market dynamics, and a 10-year patient-based sales forecast. Datamonitor's first HIV market assessment based on patient-based forecasting (PBF) methodology. Analysis of HIV market dynamics across the US and five major EU markets, supported by a large physician survey and insights of key opinion leaders. Detailed sales forecasts for the major antiretroviral classes, molecules, and brands in the US and each of the five major EU markets. Despite cost-containment efforts and an increasing threat of generic incursion, Datamonitor expects the HIV market in the US and five major EU markets to grow to $16.5bn in 2021. Major growth drivers are a continuously rising HIV prevalent population and the launch of new pipeline drugs, particularly of new single-tablet regimens (STRs). Following strong growth in the first half of the forecast period (2011–16), Datamonitor expects patent expirations of key antiretrovirals and a leveling off of HIV prevalence rates. This will likely hinder HIV market growth in the US and five major EU markets from 2017 onwards, eventually leading to declining overall sales in 2021. Understand the changing market dynamics of HIV drugs, success factors for leading brands and the commercial potential of late-stage pipeline products. Assess the impact of events such as patent expiries and new product launches on individual brands and the overall HIV antiretroviral market. Obtain full country, class, and product-specific forecasts of currently marketed and pipeline antiretrovirals from 2011 to 2021.

OVERVIEW

Summary

OVERVIEW

This product contains forecasts for HIV drugs across the US and the five major EU markets (France, Germany, Italy, Spain, and the UK) from 2011 to 2021. It has been designed for delivery in an excel data pack format, but for more detail about this HIV forecast please see the accompanying Market and Product Forecast word document and PowerPoint executive presentation (HC00083-005).

The associated report and PowerPoint presentation can be found under Latest research in the Knowledge centre, through the search function or by contacting your sales representative.

Please select the data pack option from the download menu at the side of the page to access the model.

Introduction

Despite cost-containment efforts and an increasing threat of generic incursion, Datamonitor expects the HIV market in the US and five major EU markets (France, Germany, Italy, Spain, and the UK) to grow to $16,5bn in 2021. Major growth drivers are a continuously rising HIV prevalent population and the launch of new pipeline drugs, particularly of new single-tablet regimens (STRs).

Features and benefits

Research and analysis highlights

Key questions answered

Forecasting methodology

Volume and value forecast methodology

Price and compliance assumptions

Disclaimer

Companies mentioned

To order this report:

Pathology Industry: HIV Market Forecast

More  Market Research Report

Check our  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker